Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
British Journal of Cancer|May 5, 2005
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumoursA Awada, A Hendlisz, T Gil, et al.British Journal of Cancer|November 13, 2008
Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumoursD Strumberg, B Schultheis, I A Adamietz, et al.British Journal of Cancer|November 28, 2007
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIVS Steinbild, K Mross, A Frost, et al.Journal of Cancer Research and Clinical Oncology|January 17, 2004
Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphomaS Koeppen, C C P Verstappen, R Körte, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib studyB Schultheis, G Folprecht, J Kuhlmann, et al.Biochemistry|February 15, 2001
Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpointsB D Lovett, D Strumberg, I A Blair, et al.Breast (Edinburgh, Scotland)|March 2, 2019
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA studyA Mavratzas, S Baek, B Gerber, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2006
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumorsH Richly, B F Henning, P Kupsch, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2010
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trialG von Minckwitz, H Eidtmann, S Loibl, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumorsK Mross, H Richly, N Schleucher, et al.Pageof 5